Skip to main content

Table 3 Cell growth IC50 inhibitors in a panel of cell lines

From: Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells

(A) Lymphoma cell lines
EZH2 status WSU-FSCLL WILL1 DOHH2 SC1 DB SUDLH8
HKMT-I-005 3.405 5.599 3.257 3.711 <1 <1
GSK343 2.868 17.91 6.151 12.12. <1 5.11
  W.T. W.T. W.T. W.T. Mutant Y646N W.T.
(B) Breast cancer cell lines
IC50 (μM) MDA-MB-231 MCF-7 T-47D BT-474 SkBr3 MCF10a
HKMT-I-005 4.3 7.7 8.5 2.1 7.7 >15
  1. Cell growth IC50s (in μM) for a panel of cell lines, after treatment with HKMT-I-005 or GSK343: lymphoma cell lines (A), derived from cell counting following propidium iodide staining, and breast cancer cell lines (B), derived from MTT assays for cell viability. Mutation status of EZH2 is shown for each of the lymphoma cell lines